Monopar Q2 FY26 net loss widens to $5.3 million
MNPR•Q2 loss widens as expenses rise
Monopar posted a Q2 net loss of $5.3 million, or $0.62 per share, widening from a $2.5 million loss, or $0.35 per share.
- R&D expense more than doubled to $4.77 million, driven by higher contractor and consulting costs.
- G&A expense rose 24.83% to $1.88 million, reflecting higher personnel and contractor spending.
Cash position and development update
Cash, cash equivalents and investments totaled $134.3 million; runway is expected through at least Dec. 31, 2027.
Rolling FDA NDA submission started for ALXN1840 in Wilson disease; Rare Pediatric Disease designation was granted, supporting potential priority review voucher.
